--- title: "国家知识产权局副局长卢鹏起会见瑞士罗氏集团董事会主席" description: "中国国家知识产权局副局长卢鹏起近日会见瑞士罗氏集团董事会主席施万，强调知识产权保护对营商环境的重要性，承诺对内外资企业一视同仁的保护。施万指出，知识产权是创新药企的核心竞争力，罗氏将在中国加大研发投入，推动本土医药创新成果的全球化。" type: "news" locale: "zh-CN" url: "https://longbridge.com/zh-CN/news/261886739.md" published_at: "2025-10-20T12:37:40.000Z" --- # 国家知识产权局副局长卢鹏起会见瑞士罗氏集团董事会主席 > 中国国家知识产权局副局长卢鹏起近日会见瑞士罗氏集团董事会主席施万，强调知识产权保护对营商环境的重要性，承诺对内外资企业一视同仁的保护。施万指出，知识产权是创新药企的核心竞争力，罗氏将在中国加大研发投入，推动本土医药创新成果的全球化。 近日，中国国家知识产权局副局长卢鹏起在京会见来访的瑞士罗氏集团董事会主席施万一行。卢鹏起表示，近年来，知识产权保护作为营商环境的一项重要内容，日益受到中外企业的关注。中国国家知识产权局始终坚持对内外资企业的知识产权一视同仁、依法同等保护，切实维护外商投资者合法权益。未来，中国国家知识产权局将继续秉持积极开放的态度，与各国权利人和利益相关方保持良好的交流。施万表示，知识产权是创新药企业生存与发展的核心竞争力。在中国不断完善的知识产权保护体系支撑下，越来越多的跨国制药企业对中国市场充满信心，不断深化本土化战略布局。罗氏集团将持续扩大在中国的研发投入，积极推动源自中国的医药创新成果惠及全球。 ### Related Stocks - [RHHBY.US - 罗氏(ADR)](https://longbridge.com/zh-CN/quote/RHHBY.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | Genentech Reports Positive Phase III Results For Gazyva In Primary Membranous Nephropathy | Genentech, part of the Roche Group, announced positive Phase III results for Gazyva in treating primary membranous nephr | [Link](https://longbridge.com/zh-CN/news/276037337.md) | | Roche Appoints Mark Dawson As New Head Of Roche Pharma Research And Early Development | Roche Holding AG :ROCHE HOLDING AG - APPOINTMENT OF MARK DAWSON, M.D., PH.D., AS NEW HEAD OF ROCHE PHARMA RESEARCH AND E | [Link](https://longbridge.com/zh-CN/news/276097246.md) | | Roche Announces Filing Acceptance Of New Drug Application For Giredestrant | Roche has announced that the FDA has accepted its New Drug Application for giredestrant, an investigational oral therapy | [Link](https://longbridge.com/zh-CN/news/276417142.md) | | Roche's Gazyva Meets Main Goal in Late-stage Kidney Disease Study | Roche's Gazyva Meets Main Goal in Late-stage Kidney Disease Study | [Link](https://longbridge.com/zh-CN/news/276037536.md) | | Roche Says Its Blood Cancer Drug Shows Positive Results in Trial | Roche announced that its blood cancer drug Gazyva/Gazyvaro has shown positive results in a late-stage trial for patients | [Link](https://longbridge.com/zh-CN/news/276037735.md) | --- > **免责声明**：本文内容仅供参考，不构成任何投资建议。